### FORM D



# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

## FORM D

Washington, D.C. 20549

OMB Number: 3235-0076 May 31, 2002 Expires: Estimated average burden hours per response...... 16.00

OMB APPROVAL

NOTICE OF SALE OF SECURITIES	
PURSUANT TO REGULATION D,	Pre
SECTION 4(6), AND/OR	
NIFORM I IMITED OFFFRING EXEMPTION	

SEC USE ONLY					
Prefix	Serial				
1	1				
DATE REC	EIVED				
1					

Name of Offering (☐ check if this	is an amendment and name has change	ed, and indicate	change.)	1111111
NanoRx Therapeutics, Inc. Se	eries A Convertible Preferred Stock			F9F1-
Filing Under (Check box(es) that ap	ply): ☐ Rule 504 ☐ Rule 505	⊠ Rule 5	06 □ Secti	on 4(6) ULOE
Type of Filing: New Filing	Amendment			
	A. BASIC IDENTIFICA	TION DATA		<b>8/88</b> /       <b>88/8</b> /   <b>8</b>     <b>88/88</b>     <b>8</b>     <b>8</b>
1. Enter the information requested	about the issuer			
Name of Issuer ( check if this is	an amendment and name has changed	, and indicate c	hange.)	AFRANT FIRM DOLLD I WALL WALLES HOW WILLIAM THOUGHT
NanoRx Therapeutics, Inc.				02038376
Address of Executive Offices	(Number and Street, City, Sta	te, Zip Code)	Telephone Num	ber (Including Area Code)
5820 Nancy Ridge Drive, San			858-459-894	10
Address of Principal Business Opera		te, Zip Code)	Telephone Num	ber (Including Area Code)
(if different from Executive Offices)			<u> </u>	
Brief Description of Business:				
	peptides and related compounds for	· life science ap	plications, inclu	ding therapeutics for the
treatment of humans				
Type of Business Organization				מחססרפפרה
☑ corporation [	☐ limited partnership, already formed			PROCESSED
		other (	please specify):	0000
□ business trust [	limited partnership, to be formed			P JUN 0 4 2002
	Month	Year		
Actual or Estimated Date of Incorpo	ration or Organization: 0   4	0   2	⊠ Actual	□ Estimate NANCIAI
-	nization: (Enter two-letter U.S. Posta	l Service abbre	viation for State:	FINANCIAL
	CN for Canada; FN for other			DIE
CENTED AT THE PROPERTY OF THE	51: 151 Sullada, 11: 101 Sull			

#### GENERAL INSTRUCTIONS

#### Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. o 15 U.S.C. 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where To File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signe must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, an changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E an the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

#### State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those state that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator i each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee i the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to th notice constitutes a part of this notice and must be completed.

#### ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

ia espera esperante de la companya	4	A. BASIC IDENTIF	ICATION DATA					
2. Enter the information requ								
• Each promoter of the	• Each promoter of the issuer, if the issuer has been organized within the past five years;							
• Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;								
<ul> <li>Each executive office and</li> </ul>	er and director o	of corporate issuers and o	f corporate general and i	managing partn	ers of partnership issuers;			
<ul> <li>Each general and man</li> </ul>	naging partner o	of partnership issuers.						
Check Box(es) that Apply:	⊠ Promoter	⊠ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner			
Full Name (Last name first, if	individual)							
Flagship Ventures								
Business or Residence Addres 150 CambridgePark Dri	s (Number and ve, Cambridge	Street, City, State, Zip ( e <b>, MA 02140</b>	Code)					
Check Box(es) that Apply:		☐ Beneficial Owner	Executive Officer	⊠ Director	☐ General and/or  Managing Partner			
Full Name (Last name first, ifAfeyan, Noubar B.	individual)							
Business or Residence Addres					10 10 10 10 10 10 10 10 10 10 10 10 10 1			
Check Box(es) that Apply:	0 €ambridgel □ Promoter	Zark Drive, Cambridge  ☐ Beneficial Owner	MA 02140 ☐ Executive Officer	Director     □	☐ General and/or			
Check Box(es) that Apply.		D Belleficial Owler		M Director	Managing Partner			
Full Name (Last name first, if Palandjian, Leon A.								
Business or Residence Addres c/o Flagship Ventures 15								
Check Box(es) that Apply:			Executive Officer	⊠ Director <sub>i</sub> .	General and/or Managing Partner			
Full Name (Last name first, if Nami, Nader					226			
Business or Residence Addres c/o Frazier & Co. 601 U								
Check Box(es) that Apply:	☐ Promoter	□ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner			
Full Name (Last name first, if	•							
Applied Genomics Tech			7 1 \					
Business or Residence Addres 150 CambridgePark Dri	,		Lode)					
Check Box(es) that Apply:		Beneficial Owner	Executive Officer	□ Director :	☑ General and/or			
					Managing Partner			
Full Name (Last name first, if NewcoGen Equity Inves								
Business or Residence Addres 2 150 CambridgePark Dri	s (Number and		Code)	Tree.				
	☐ Promoter	⊠ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner			
Full Name (Last name first, if	individual)		,		<u> </u>			
Fraizer Healthcare, IV,	LP							
Business or Residence Addres	s (Number and	l Street, City, State, Zip (	Code)	•				

601 Union Street, Suite 3300, Seattle, WA 98101

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

Check Box(es) that Apply:	☐ Promoter	⊠ Beneficial Owner	☐ Executive Officer	☐ Director	General and/or Managing Partner
Full Name (Last name first, : Reza Ghadiri	if individual)				,
Business or Residence Address 5133 Seagrove Ct. San	`	0	, , , , , , , , , , , , , , , , , , ,		
Check Box(es) that Apply		. ⊠ Beneficial Owner 1	□ Executive Officer	⊠ Director	General and/or Managing Partner
Full Name (Last name first,  Mahmoud Ladjevardi		A Company of the Comp			
Business or Residence Addr 5820 Nancy Ridge Driv			at an artist adjusted the transfer of the second		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first,	if individual)				
Business or Residence Addr	ess (Number and	Street, City, State, Zip	Code)		
Check Box(es) that Apply:	Promoter :-	☐ Beneficial Owner	Executive Officer	Director	☐ General and/or
Full-Name (Last name first,	if individual)				77
Business or Residence Addr	ess (Number and	Street, City, State, Zip	Code)		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first,	if individual)			•	
Business or Residence Addr	ess (Number and	Street, City, State, Zip	Code)		
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner □	Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first,	if individual)	The state of the s			
Business or Residence Addr	ess (Number and	Street, City, State, Zip	Code)		

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

					В. П	NFORMA	TION AB	OUT OFF	ERING				
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?						Yes □	No ⊠					
	Answer also in Appendix, Column 2, if filing under ULOE.								_				
									\$2	\$25,000			
												Yes	No
	Does the offering permit joint ownership of a single unit?												
4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.													
Full	Name	(Last nar	ne first, if	individual	1)								
	N/A_												
Busi	ness o	r Residen	ce Addres	s (Numbe	r and Stree	et, City, Sta	ate, Zip Co	de)					
Nam	ne of A	ssociated	Broker or	Dealer	<del>, , , , , , , , , , , , , , , , , , , </del>		· · · · · · · · · · · · · · · · · · ·		***************************************			·	
							licit Purcha						
	(Checl	k "All Sta	ites" or ch	eck indivi	dual States	s)	••••••	•••••	**************			🗆 All S	States
[A	AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
_	IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
_	/IT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
	RI] 	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]
Full	Name	(Last nar	ne first, if	individual	1)								
Busi	iness o	r Residen	ce Addres	s (Numbe	r and Stree	et, City, Sta	ate, Zip Co	de)				·.	
Nan	ne of A	ssociated	Broker or	Dealer					****				<del></del>
							licit Purcha					- A 11 (	
	•					•							
_	AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
-	IL]	[IN]	[IA]	[KS]	[KY]	[LA] [NM]	[ME]	[MD]	[MA] [ND]	[MI]	[MN] [OK]	[MS]	[MO] [PA]
_	ИТ] RI]	[NE] [SC]	[NV] [SD]	[NH] [TN]	[NJ] [TX]	[UT]	[NY] [VT]	[NC] [VA]	[WA]	[OH] [WV]	[WI]	[OR] [WY]	[PR]
			ne first, if			[01]	[, -]	[ ]	[ ]		L 11-3	[]	
		7											
Busi	iness o	r Residen	ice Addres	s (Numbe	r and Stree	et, City, St	ate, Zip Co	de)					
Nan	ne of A	ssociated	Broker o	r Dealer									
							licit Purcha					🗆 All S	States
	(Onco.	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
-	IL]	[IN]	[A2]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
	AT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
_	RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

## C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box $\square$ and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.				
	Type of Security	o	Aggregate ffering Price	Al	Amount Iready Sold
	Debt	\$		\$	
	Equity			-	
	☐ Common ☐ Preferred	\$	\$6,000,000	\$	6,000,000
	Convertible Securities (including warrants)	\$		\$	
	Partnership Interests	\$		\$	
	Other (Specify)	\$		\$	
	Total	\$		\$	
	Answer also in Appendix, Column 3, if filing under ULOE.			-	
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."				Aggregate
					llar Amount
		Nu	mber Investors		f Purchases
	Accredited Investors		6	\$	6,000,000
	Non-accredited Investors			\$	
	Total (for filings under Rule 504 only)			\$	
	Answer also in Appendix, Column 4, if filing under ULOE.			•	
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1.  Type of Offering		Type of	Do	llar Amount
	•		Security		Sold
	Rule 505			\$ .	
	Regulation A			. \$	
	Rule 504			\$	
	Total			\$	
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.  Transfer Agent's Fees			\$	
	Printing and Engraving Costs			\$	
	Legal Fees		$\boxtimes$	\$	25,000
	Accounting Fees			\$	
	Engineering Fees			\$	
٠	Sales Commissions (specify finders' fees separately)			\$	
	Other Expenses (identify)			\$	
	Total			\$	25,000

	C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSE	S AND USE OF P	ROCEEDS		
_	b. Enter the difference between the aggregate offering price given in response to Par Question 1 and total expenses furnished in response to Part C - Question 4.a. This differenthe "adjusted gross proceeds to the issuer."	t C -	\$		5,975,000
5.	Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed used for each of the purposes shown. If the amount for any purpose is not known, furnise stimate and check the box to the left of the estimate. The total of the payments listed equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question above.	sh an must			
	above.	Payment Officer Director Affiliat	⁻s, s &	•	ments To Others
	Salaries and fees	□ \$		\$	
	Purchase of real estate	□ \$		} \$	
	Purchase, rental or leasing and installation of machinery and equipment	□ \$		] \$	
	Construction or leasing of plant buildings and facilities	□ \$		\$	
	Acquisition of other businesses (including the value of securities involved this offering that may be used in exchange for the assets or securities another issuer pursuant to a merger)	of		] \$	
	Repayment of indebtedness			] \$	
	Working capital	□ \$		<b>]</b> \$ <sup>*</sup>	5,975,000
	Other (specify):	□ \$		] \$	
	Column Totals	□ \$		] \$	
	Total Payments Listed (column totals added)	⊠ \$ <u> </u>	<u>5,975</u>	000,	
	D. FEDERAL SIGNATURE				
50 up	ne issuer has duly caused this notice to be signed by the undersigned duly author 15, the following signature constitutes an undertaking by the issuer to furnish to the son written request of its staff, the information furnished by the issuer to any non-arrangement of the staff	ne U.S. Securities	and Exchange	e Co	mmission,
ssu	ner (Print or Type)	D	ate	-	
Var	noRx Therapeutics, Inc	N	lay 16, 2002		
	me of Signer (Print or Type)  Title of Signer (Print or Type)		· · · · · · · · · · · · · · · · · · ·		
E <u>d</u> v	ward D. Freedman Secretary				

**ATTENTION** 

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)